Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy
about
Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies.GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroGoing back to class I: MHC and immunotherapies for childhood cancer.Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memoryEx vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancerMetronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma modelRepeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsCergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine.Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.Targeting autophagy in cancer.BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity.Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.Therapeutic blockade of Foxp3 in experimental breast cancer models.Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer.Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitorLDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune responseAnti PD-1 treatment increases [F]FDG uptake by cancer cells in a mouse B16F10 melanoma modelIntegrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
P2860
Q33428144-42672405-C583-4DD6-941D-DDA6B4D6E7FCQ33814776-264D994D-A2F2-428C-9003-CB7EA4939D7DQ34615021-139FCC9E-7849-42DE-9A9D-F607F9B06DC1Q35117552-8A6665BB-FE85-4D07-89BD-2B8884050BBEQ35799297-1BE2E5B6-695B-44C0-9D3A-93A32877FCD7Q35828574-536E9064-5C30-4799-8182-636A097E3E5BQ36101917-DBC24430-302A-4E31-ABBC-351DDC549D21Q36600960-DA28D35F-2D80-4D52-98E8-FBE6C7E9E85EQ36710927-6E351E5B-2B0C-4A4A-9DFB-B2240EAED0F5Q36827406-3CE2BF9C-7937-4AEF-B5D3-FEB889F6B612Q37741534-39272A32-F520-4793-B8D3-0D10CE3D40E9Q38683494-EF411A9F-B839-4DCC-8A2D-774371360588Q39164068-3BD93EE7-99C9-4A76-B4FD-AFE43CE00D79Q39637191-28DC589E-8B68-4FEF-83E0-AEEA6702645CQ41715903-4ADB996C-125C-4A85-956C-A2BAE36CCF16Q41886564-E2E0905E-2C59-46E1-BA35-960F02987346Q41912265-5B82B640-C284-475C-A814-6FED70A8207BQ42731020-3034E09C-EE1D-4545-B3AB-85E9E0E682C1Q47305361-7E97886D-9549-46BF-961B-B67ACA746647Q47696309-AA9D33BC-DA75-44C8-B08C-781261C85971Q48325267-F8DAC29D-F6E1-4961-B3F1-D3C30841D777Q48505173-1AB42D74-B69B-4D4F-A79B-A8DD3978B5E2Q50538951-645B67D4-74F6-48D8-8F4C-ACE842C59DA7Q50676824-BCF8CAF1-9E92-4228-96DD-9E84ECF8715BQ51615851-254E2AC8-FA4B-4771-B4CE-A7B781484D09Q52655339-FF07F6D9-8494-4F41-AD55-FFDF8D6F64E9Q52796907-065B64BB-E9F6-445D-B534-25C450196983Q57137831-4FFB111C-DCC6-4738-AE00-AB6FA8ED92BDQ58701330-4F4F5909-1C7D-4803-B4DD-1E49C8A56305Q58774383-7A9C3935-BB36-4C34-B3A9-6E753D7E7F4CQ59127131-65CA1043-E58B-406D-83FE-55550754546C
P2860
Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Immunogenicity of murine solid ...... and response to immunotherapy
@en
Immunogenicity of murine solid ...... and response to immunotherapy.
@nl
type
label
Immunogenicity of murine solid ...... and response to immunotherapy
@en
Immunogenicity of murine solid ...... and response to immunotherapy.
@nl
prefLabel
Immunogenicity of murine solid ...... and response to immunotherapy
@en
Immunogenicity of murine solid ...... and response to immunotherapy.
@nl
P2093
P2860
P50
P1476
Immunogenicity of murine solid ...... and response to immunotherapy
@en
P2093
Alan L Epstein
Connor H Church
John R Ohlfest
Keegan Barry-Holson
Peisheng Hu
Saman S Karimi
P2860
P304
P356
10.1097/01.CJI.0000436722.46675.4A
P577
2013-11-01T00:00:00Z